Every material Form 8-K Atrium Therapeutics, Inc. has filed with the SEC since October 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 2, 2026, Atrium Therapeutics announced a November 6 poster presentation at the Hypertrophic Cardiomyopathy Medical Society meeting, held during the American Heart Association Scientific Sessions 2026 in Chicago. The poster covers nonclinical results for lead candidate ATR 1072 in a new mouse model of PRKAG2 syndrome, where the company reports reversal of cardiac glycogen accumulation and improvement in hypertrophy and ECG parameters. The filing contains no financial results, and the company notes that nonclinical results may not predict human outcomes.
Poster presentation on November 6, 2026 at 5:30 p.m. CT, Presentation Number HCM32, Chicago
In mice, a single dose of mATR 1072 after three weeks of established disease reversed cardiac glycogen accumulation and improved hypertrophy and ECG parameters
Company expects initial proof-of-concept data from the Phase 1/2 Corventis trial in the second half of 2027
Atrium Therapeutics announced that the first patient has been dosed in the Phase 1/2 Corventis trial of ATR 1072, its lead investigational therapy for PRKAG2 syndrome, a rare genetic heart disease with no approved therapies. The company expects initial proof-of-concept data in the second half of 2027, so the milestone does not yet bear on the company's clinical or financial results.
First patient dosed in the Corventis trial, announced October 27, 2026
Global trial plans to enroll approximately 37 participants
Initial proof-of-concept data expected in the second half of 2027
Primary endpoint is incidence of treatment-emergent adverse events
On October 7, 2026, Atrium Therapeutics agreed to sell 5,170,384 common shares at $7.93 each, plus pre-funded warrants for up to 1,134,930 shares, to accredited investors, for expected gross proceeds of about $50 million before fees. The company says the proceeds, together with existing cash, will fund operations through 2028, and that shares outstanding will rise to 22,276,027 after the offering, which shareholders should weigh against their stake.
5,170,384 common shares sold at $7.93 per share; pre-funded warrants for up to 1,134,930 shares sold at $7.929 each.
Expected gross proceeds of about $50 million before placement agent fees and offering expenses; closing expected on or about October 9, 2026.
Company estimates net proceeds plus existing cash will fund operations through 2028; proceeds are for lead programs, other research, working capital and general corporate purposes.
Company must file a resale registration statement with the SEC within 50 days of the closing date; 22,276,027 shares will be outstanding after the offering.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Atrium Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →